Luis Diaz Net Worth

Luis Diaz biography

Dr. Luis A. Diaz Jr., M.D. serves as Independent Director of the Company. Dr. Diaz has served as the head of the solid tumor oncology division and a faculty member at the Memorial Sloan Kettering Cancer Center since December 2016. From 2004 to December 2016, Dr. Diaz was a faculty member and physician at Johns Hopkins University School of Medicine. Dr. Diaz is also a founder and board member, and from 2010 to April 2016 served as president, chief executive officer and chief medical officer, of Personal Genome Diagnostics Inc., a private cancer genome analysis company. He received his M.D. from the University of Michigan, where he also received his B.A. in Microbiology.

What is the salary of Luis Diaz?

As the Independent Director of Jounce Therapeutics Inc, the total compensation of Luis Diaz at Jounce Therapeutics Inc is $87,304. There are 11 executives at Jounce Therapeutics Inc getting paid more, with Kimberlee Drapkin having the highest compensation of $2,032,250.

How old is Luis Diaz?

Luis Diaz is 49, he's been the Independent Director of Jounce Therapeutics Inc since 2017. There are 15 older and no younger executives at Jounce Therapeutics Inc. The oldest executive at Jounce Therapeutics Inc is Dr. Louis M. Weiner M.D., 69, who is the Founder.

What's Luis Diaz's mailing address?

Luis's mailing address filed with the SEC is 780 Memorial Dr, Cambridge, MA 02139, USA.

Insiders trading at Jounce Therapeutics Inc

Over the last 8 years, insiders at Jounce Therapeutics Inc have traded over $39,574,093 worth of Jounce Therapeutics Inc stock and bought 724,587 units worth $10,288,083 . The most active insiders traders include Kevin Ctang Capital Managem..., Harbor Master Investors (Ca... e Rock Ventures Ii, L.P.Third.... On average, Jounce Therapeutics Inc executives and independent directors trade stock every 39 days with the average trade being worth of $171,610. The most recent stock trade was executed by Richard /Ca/ Murray on 4 April 2023, trading 39,228 units of JNCE stock currently worth $72,572.

What does Jounce Therapeutics Inc do?

Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company dedicated to transforming the treatment of cancer by developing therapies that enable the immune system to attack tumors and provide long-lasting benefits to patients through a biomarker-driven approach. Jounce currently has multiple development stage programs ongoing while simultaneously advancing additional early-stage assets from its robust discovery engine based on its Translational Science Platform. Jounce's highest priority program, JTX-8064, is a LILRB2 (ILT4) receptor antagonist shown to reprogram immune-suppressive tumor associated macrophages to an anti-tumor state in preclinical studies. A Phase 1 clinical trial, named INNATE, for JTX-8064 as a monotherapy and in combination with JTX-4014, Jounce's internal PD-1 inhibitor, or pembrolizumab is currently enrolling patients with advanced solid tumors. Jounce's most advanced product candidate, vopratelimab, is a monoclonal antibody that binds to and activates ICOS, and is currently being studied in the SELECT Phase 2 trial. JTX-4014 is a PD-1 inhibitor intended for combination use in the INNATE and SELECT trials and with Jounce's broader pipeline. Additionally, Jounce exclusively licensed worldwide rights to JTX-1811, a monoclonal antibody targeting CCR8 and designed to selectively deplete T regulatory cells in the tumor microenvironment, to Gilead Sciences, Inc.

Jounce Therapeutics Inc executives and stock owners

Jounce Therapeutics Inc executives and other stock owners filed with the SEC include:

• Kimberlee Drapkin,
  Chief Financial Officer, Treasurer
• Richard Murray,
  President, Chief Executive Officer, Director
• Dr. Richard Murray,
  Pres, CEO & Director
• Hugh Cole,
  Chief Business Officer, Head of Corporate Development
• Elizabeth Trehu,
  Chief Medical Officer
• Hugh M. Cole,
  Chief Bus. Officer & Head of Corp. Devel.
• Kimberlee Cobleigh Drapkin CPA, CPA,
  CFO & Treasurer
• Dr. Elizabeth G. Trehu,
  Chief Medical Officer
• Perry Karsen,
  Independent Chairman of the Board
• Barbara Duncan,
  Independent Director
• J. Duncan Higgons,
  Independent Director
• Luis Diaz,
  Independent Director
• Cary Pfeffer,
  Independent Director
• Robert Tepper,
  Independent Director
• Robert Kamen,
  Independent Director
• Robert Iannone,
  Independent Director
• Dr. Stephen G. Farrand Ph.D.,
  Chief Technical Officer
• Dr. Louis M. Weiner M.D.,
  Founder
• Dr. Padmanee Sharma M.D., Ph.D.,
  Founder
• Dr. Thomas F. Gajewski M.D., Ph.D.,
  Founder
• Dr. Louis M. Weiner,
  Founder
• Dr. Padmanee Sharma,
  Founder
• Dr. Drew Mark Pardoll M.D., Ph.D.,
  Founder
• Dr. Robert D. Schreiber,
  Founder
• Dr. Thomas F. Gajewski,
  Founder
• Dr. James P. Allison,
  Founder
• Switzerland Llccelgene Corp...,
  
• Rock Ventures Ii, L.P.Third...,
  
• Harbor Master Investors (Ca...,
  10% owner
• Biosciences, Llc Concentra,
  10% owner
• Luisa Salter Cid,
  Director
• Rock Ventures Ii, L.P.Third...,
  
• Kevin Ctang Capital Managem...,
  
• Jigar Raythatha,
  Director
• Rock Ventures Iii, L.P.Thir...,